FLT3-ITD allelic ratio
How much of the FLT3 gene in the leukaemia carries the internal duplication. Once used to grade risk; now less important because FLT3 inhibitors help regardless.
Ratio of mutant to wild-type FLT3-ITD alleles by fragment analysis; ≥0.5 was 'high'. ELN 2017 used it for risk; ELN 2022 removed it, treating all FLT3-ITD as intermediate risk given midostaurin and quizartinib benefit across ratios. Still reported by many labs and relevant to interpreting older trials.
Pages like this
not linked directly; found by shared links- ProductMidostaurin
Shares RATIFY (CALGB 10603), FLT3, Acute myeloid leukaemia.
- PairingFLT3 inhibitor + intensive chemotherapy
Shares RATIFY (CALGB 10603), FLT3, Acute myeloid leukaemia.
- TrialADMIRAL
Shares FLT3, Acute myeloid leukaemia.
- IdeaMRD-guided transplant decisions in intermediate-risk AML
Shares ELN 2022 risk classification, Acute myeloid leukaemia.
- PersonEunice S. Wang
Shares FLT3, Acute myeloid leukaemia.
- TrialQuANTUM-First
Shares FLT3, Acute myeloid leukaemia.
- TechnologyCytogenetics and FISH
Shares ELN 2022 risk classification, Acute myeloid leukaemia.
- TargetNPM1 mutation
Shares ELN 2022 risk classification, FLT3, Acute myeloid leukaemia.